Report of a workshop sponsored by the European Organisation for Research and Treatment of Cancer (EORTC) on the treatment of primary malignant brain tumours

Hildebrand, J; Thomas, D G
February 1991
Journal of Neurology, Neurosurgery & Psychiatry;Feb1991, Vol. 54 Issue 2, p182
Academic Journal
No abstract available.


Related Articles

  • EORTC's Regulatory Affairs Unit.  // Applied Clinical Trials;Sep2002, Vol. 11 Issue 9, p61 

    Provides information on the European Organisation for Research Treatment of Cancer (EORTC), an international nonprofit association, created in 1962 under Belgian law, that introduced in Europe a multidisciplinary approach to cancer clinical research. Aims of the EORTC; Provision of support to...

  • AACR Roundup.  // BioWorld Today;11/17/2011, Vol. 22 Issue 224, p8 

    The article reports on data presented at the American Association for Cancer Research (AACR)-National Cancer Institute (NCI)- European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.

  • Meunier crafts new approach to European clinical cancer research. Steimle, Sabine // JNCI: Journal of the National Cancer Institute;02/19/97, Vol. 89 Issue 4, p277 

    Reports on the crafting of an approach to European cancer research by Francoise Meunier, director general of the European Organization for Research and Treatment of Cancer (EORTC). Meunier's career history and achievements; Collaboration of EORTC with pharmaceutical industry; Creation of a...

  • Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Centre symptom study. D. J. Storey; R. A. Waters; C. J. Hibberd; R. W. Rush; A. T. Cargill; L. R. Wall; M. T. Fallon; V. A. Strong; J. Walker; M. Sharpe // Annals of Oncology;Nov2007, Vol. 18 Issue 11, p1861 

    Background: Fatigue is associated with cancer and its treatment but we know little about how many and which patients suffer fatigue of clinical severity. We aimed to determine the prevalence of clinically relevant fatigue (CRF) and its associations in outpatients with various cancer diagnoses....

  • EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Pallis, A. G.; Ring, A.; Fortpied, C.; Penninckx, B.; Van Nes, M. C.; Wedding, U.; vonMinckwitz, G.; Johnson, C. D.; Wyld, L.; Timmer-Bonte, A.; Bonnetain, F.; Repetto, L.; Aapro, M.; Luciani, A.; Wildiers, H. // Annals of Oncology;Aug2011, Vol. 22 Issue 8, p1922 

    Background: Due to the aging of the population, the number of older patients diagnosed with a malignant disease is increasing. A multidisciplinary approach to the senior adult cancer patient is mandatory, to assure optimal diagnosis and therapeutic management.Design: European Organisation for...

  • Harmful impact of EU clinical trials directive.  // BMJ: British Medical Journal (International Edition);3/4/2006, Vol. 332 Issue 7540, p501 

    The author examines why academic clinical research in cancer appears to have no future in Europe. Investigator initiated academic clinical research is under threat from a European Union (EU) directive aimed at protecting patients and improving research standards. The largest independent cancer...

  • Commentary: Fifty Years of the European Organisation for Research and Treatment of Cancer (EORTC) - Making the Difference for the European Oncology Community. MEUNIER, FRANÇOISE; LAWLER, MARK; PINEDO, H.M. // Oncologist;Jun2012, Vol. 17 Issue 6, pe6 

    The authors discuss the contribution made by the European Organisation for Research and Treatment of Cancer (EORTC) in the last 50 years on the European oncology community. The history and evolution of the EORTC since 1962 as a key enabler of clinical and translational research in Europe is...

  • Endometrial cancer module valid in EORTC questionnaire.  // PharmacoEconomics & Outcomes News;11/13/2010, Issue 616, p9 

    The article discusses research on the reliability and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire--Endometrial Cancer Module (EORTC QLQ EN24), by E. Greimel and colleagues, published in the September 2010 issue of the "European Journal...

  • Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire. Pistevou-Gombaki, Kiki; Eleftheriadis, Nikos; Plataniotis, Georgios A; Sofroniadis, Ioannis; Kouloulias, Vassilis E // Palliative Medicine;Apr2003, Vol. 17 Issue 3, p257 

    Background and aim: While octreotide has been used in palliative treatment of hepatocellular carcinoma and neuroendocrine tumours with good results, little is known about the possible role of this in palliative treatment of hepatic metastases. Material and methods: We present our experience from...

  • Functional Biomarkers Could Solve Some Diagnostic Woes. Breindl, Anette // BioWorld Insight;10/28/2013, Vol. 21 Issue 44, p2 

    The article offers information related to the 2013 molecular target and cancer therapeutics conference of the American Association for Cancer Research (AACR), the U.S. National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC) (AACR-NCI-EORTC) held...


Read the Article


Sign out of this library

Other Topics